Answers are grounded in this paper and cite their sources.
Autologous-induced pluripotent stem cells (iPSCs) may eventually be used in cell replacement therapies to treat a wide range of diseases and have been touted as a solution to the vexing problem of immune rejection in this context. Emerging evidence suggests, however, that ostensibly histocompatible iPSCs may be rejected following transplantation. Here, we review the mechanisms that contribute to immunogenicity in iPSCs and forward approaches to permit their acceptance in potential cell replacement therapies.
No takes yet. Share an insight, caveat, or question.
Boyd et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: